FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Robinson John Edward
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/31/2021 

3. Issuer Name and Ticker or Trading Symbol

Cogent Biosciences, Inc. [COGT]
(Last)        (First)        (Middle)

C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Scientific Officer /
(Street)

CAMBRIDGE, MA 02140      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)  (1)3/31/2031 Common Stock 500000 $8.78 D  

Explanation of Responses:
(1) This stock option shall vest over a four year period as follows: 1/4th of the option shall vest one year after the vesting start date; then 1/48th of the option shall vest monthly over the remaining three year period.

Remarks:
Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Robinson John Edward
C/O COGENT BIOSCIENCES, INC.
200 CAMBRIDGE PARK DRIVE, SUITE 2500
CAMBRIDGE, MA 02140


Chief Scientific Officer

Signatures
/s/ Ryan Murr, Attorney-in-Fact4/15/2021
**Signature of Reporting PersonDate

Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Unum Therapeutics Charts.
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Unum Therapeutics Charts.